title: High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease.
authors.forename: D
authors.initials: D
authors.lastname: Telio
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
authors.forename: D
authors.initials: D
authors.lastname: Forrest
authors.forename: L
authors.initials: L
authors.lastname: Zypchen
authors.forename: M
authors.initials: M
authors.lastname: Barnett
authors.forename: T
authors.initials: T
authors.lastname: Nevill
authors.forename: K W
authors.initials: KW
authors.lastname: Song
mesh_terms: D000328:Adult; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism / Q000628:therapy*; D010265:Paraproteinemias / Q000378:metabolism*; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D008558:Melphalan